All entries for: Layoffs

August 6, 2026

Emergent Biosolutions

Layoffs

Gaithersburg, Maryland

501-1,000 employees

“To align resourcing to current needs, Emergent BioSolutions is restructuring its business, a move that includes letting go of 93 employees across the company and eliminating 21 vacant positions. Emergent announced the plans in its second quarter earnings release and provided additional details in a related SEC filing.

The layoffs represent a small number of the company’s overall workforce, which was about 900 employees as of Dec. 31, 2025.

Emergent, which develops and manufactures medicines for diseases including smallpox and makes Narcan, which treats opioid overdoses, did not specify which locations the workforce reduction will affect. However, the announcement noted the closure of wet laboratories in Gaithersburg, Maryland, where the company is based.

The restructuring includes eliminating the role of chief medical officer, head of research and development, pushing Simon Lowry out of Emergent effective Aug. 19. The company is also creating a new “growth organization” that combines research and development, business development and strategy into one function. Stephanie Duatschek will lead that team in her new role as executive vice president, chief growth officer. Previously, she was senior vice president, chief global strategy and franchise development officer.

Emergent expects to incur costs of $10 million to $11.5 million in connection with the restructuring. As of June 30, the company’s capital resources included $139.7 million in cash and cash equivalents.”

Disease Area: Antiviral, Infectious Diseases

Drug Type: Biologic, Small Molecule

Source

August 5, 2026

Pfizer - New York

Layoffs

New York, NY

10,000+ employees

“Pfizer is adding $2.5 billion in cuts to an ongoing restructuring, with much of the new reduction coming from technology and simplification efforts across the New York pharma’s commercial, R&D and manufacturing functions.

The cuts under Pfizer’s Realigning Our Cost Base Program are expected to save $1 billion, the company announced Aug. 4 in its second-quarter earnings release. Most savings will occur between 2027 and 2029, but not for free: the program carries a one-time cost of $2 billion for digital enablement, implementation and severance.

A company spokesperson declined to give further details on how severance will be paid, whether any jobs will be affected, or what technological changes are planned.”

Disease Area: Antiviral, Cardiology, Dermatology, Gastrointestinal, Immune Diseases, Infectious Diseases, Metabolic Diseases, Multiple, Oncology

Drug Type: Biologic, Small Molecule

Source

July 29, 2026

GSK/England

Layoffs

London, England

10,000+ employees

“GSK’s $2.5 billion restructuring over the next three years will include global job cuts, the company announced in a July 29 media call. CEO Luke Miels declined to say how many employees the U.K. pharma will let go, saying he wanted his team to discuss the changes with staff first and would provide an update once the plans are implemented. He framed the effort as a reallocation toward new medicines.

GSK intends to use part of the expected savings to keep funding its late-stage portfolio and pipeline. Some will also go toward improving margins and profitability ahead of the 2028 U.S. patent expiry for its HIV medicine dolutegravir.”

Disease Area: Antiviral, Immune Diseases, Multiple, Oncology, Respiratory Diseases

Drug Type: Biologic, Small Molecule

Source

July 23, 2026

Clinuvel Pharmaceuticals

Layoffs

Melbourne, Victoria

51-200 employees

“As part of a reorganization to focus resources on the U.S. market, CLINUVEL PHARMACEUTICALS will cut its global workforce by 10% to 20%, the company announced Thursday. With 104 employees as of June 15 per an SEC filing, the layoffs could affect as many as 21 people.

The biopharma, which develops therapies for genetic, metabolic and dermatological disorders, will relocate its headquarters from Australia to New York in early 2027 to strengthen regulatory engagement and commercial partnerships. It noted that its late-stage programs, especially in vitiligo, mainly target the U.S. patient population, which it estimates at about 6 million.

CLINUVEL said the workforce reduction realigns operating costs with current revenue and near-term clinical and commercial priorities. It also called the restructuring a prerequisite to accessing deeper, more liquid capital pools in the U.S.”

Disease Area: Dermatology, Rare Disease

Drug Type: Biologic

Source

July 8, 2026

Novartis

Layoffs

Basel, Baselstadt

10,000+ employees

“In its largest layoff round this year, Novartis is cutting its East Hanover, New Jersey, workforce for a fourth time, letting go of 322 employees and bringing the site’s total to 572. The cuts take effect Oct. 2, per a WARN Act notice.

The first three rounds at the Swiss pharma’s East Hanover site were disclosed in March, April and May, affecting 114, 60 and 76 employees respectively. All are effective this year.

In total, Novartis has announced or disclosed at least 792 job cuts in 2026. In May, the company confirmed to BioSpace it was laying off a select number of staff in its biomedical research arm. That same month, it announced the closure of a production site in Wehr, Germany by the end of 2028, eliminating 220 jobs.”

Disease Area: Cardiology, Dermatology, Immune Diseases, Multiple, Neurological Diseases, Oncology

Drug Type: Biologic, Small Molecule

Source

July 6, 2026

BioNTech

Layoffs

Mainz, Rhineland-Palatinate

1,000-5,000 employees

“BioNTech will close its Berlin-based subsidiary JPT Peptide Technologies by year’s end, cutting about 140 jobs as it focuses on its late-stage oncology pipeline, per a quarterly report. JPT is a contract manufacturer specializing in peptide-based products and services.

The German company is also closing manufacturing sites in Idar-Oberstein and Marburg, along with CureVac’s facilities in Germany and abroad, by the end of next year, plus a Singapore site by Q1 2027. Those closures affect roughly 1,860 jobs.”

Disease Area: Oncology

Drug Type: Biologic

Source

June 29, 2026

BioCryst

Layoffs

Durham, NC

501-1,000 employees

“BioCryst is exiting internal discovery work and will close its Birmingham, Alabama site by the end of 2026. The company said it will now prioritize external innovation over its own discovery programs. A spokesperson declined to say how many jobs the shutdown will affect.

The spokesperson told BioSpace on June 29 that the company is committed to supporting affected employees through the transition, and that commercial and clinical programs continue as planned.

The site is BioCryst’s Discovery Center of Excellence. The move comes about a month after the company dropped avoralstat, its diabetic macular edema candidate in Phase 1b testing, to concentrate on its rare disease pipeline.”

Disease Area: Rare Disease

Drug Type: Biologic, Small Molecule

Source

June 23, 2026

Tourmaline Bio

Layoffs

New York, NY

1-50 employees

Tourmaline Bio said goodbye to 60 employees at its New York headquarters months after being swallowed by Novartis.

The workforce reduction stems from the closure of a Tourmaline site at 27 West 24th in New York, according to a Workers Adjustment and Retraining Notification (WARN) alert for the state. The layoffs took effect May 29, though the notice was only posted last week.

Novartis moved to acquire Tourmaline in September last year, putting around $1.4 billion on the line on a fully diluted basis, the pharma said at the time. The transaction closed in late October.

Novartis has conducted several rounds of layoffs this year, including one that takes effect in August and will leave 76 New Jersey workers jobless. The pharma also announced in May that it would shutter a Germany facility by the end of 2028, which will affect 220 jobs. Novartis ran two other cycles of terminations—one in March and another in April—which together affected more than 170 staff in New Jersey.

Disease Area: Cardiology, Immune Diseases, Multiple

Drug Type: Biologic

Source

June 12, 2026

Genentech

Layoffs

South San Francisco, CA

10,000+ employees

Genentech has made changes to its research and early development group (gRED) that include parting ways with a high-profile executive who had been with the company since 1997. The South San Franciso–based biotech confirmed to BioSpace the “targeted adjustments” and departure of Vishva Dixit, who most recently served as vice president and senior fellow, physiological chemistry, research biology.

The restructuring is intended to ensure the Roche subsidiary’s capabilities and investments align with its core therapeutic areas, advance its portfolio and deliver transformative medicines to patients faster, according to Genentech. A spokesperson declined to share specific information about the layoffs, including how many employees were affected.

Endpoints News reported that Genentech is closing infectious disease and physiological chemistry units while downsizing other teams. Also, in addition to Dixit, other key departures include Todd McDevitt, vice president and head of cell therapy, and Man-Wah Tan, a vice president and senior fellow of infectious diseases, the media outlet reported.

Disease Area: Dermatology, Immune Diseases, Infectious Diseases, Multiple, Oncology, Rare Diseases, Respiratory Diseases

Drug Type: Biologic, Small Molecule

Source

June 10, 2026

Fulcrum Therapeutics

Layoffs

Cambridge, MA

51-200 employees

Just days after announcing it was exploring strategic alternatives for the business after ending development of its lead asset, Fulcrum Therapeutics is cutting 85% of its workforce, according to an SEC filing. The Cambridge, Massachusetts–based biotech will lay off 48 of its 57 employees as part of a restructuring plan approved May 31 meant to significantly reduce operating expenses and preserve capital. Fulcrum informed staff on June 4.

The company announced June 1 it is discontinuing development of pociredir in sickle cell disease, as it no longer sees a viable regulatory path for the drug. Fulcrum noted that the FDA had recently raised concerns regarding pociredir’s benefit-risk profile in that indication.

The biotech expects to mostly complete its layoffs during the second quarter. Fulcrum estimated it will incur about $4.2 million in costs in connection with its restructuring plan, consisting mostly of severance, benefits and related expenses.

Disease Area: Hematology, Multiple, Rare Diseases

Drug Type: Biologic, Small Molecule

Source